Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexacerfont in Major Depressive Disorder
NCT00135421Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2005
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pexacerfont in major depressive disorder (MDD) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Hamilton Depression Rating Scale at 8 weeks. Started Nov 2005; status: completed.
02
Drugs
pexacerfont
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00135421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135421.